320-x-100_uti_gold.jpg" alt="Advertisement">
India plans incentives for diabetes, obesity drug makers in 2026, government official says
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
India is planning to offer incentives to promote local manufacturing of GLP-1 drugs used to treat diabetes and obesity, in 2026, a top government official said on Friday.
GLP-1 drugs, originally approved to treat diabetes, are also widely being used to treat obesity as they slow digestion, helping patients feel full longer.
Danish drugmaker Novo Nordisk's patent on semaglutide - a GLP-1 agonist and the key ingredient in its wildly popular obesity drug Wegovy and diabetes drug Ozempic - is set to expire in India in 2026, industry experts say.
